Short Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Expands By 66.2%

Athira Pharma, Inc. (NASDAQ:ATHA) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 1,650,000 shares, a growth of 66.2% from the August 31st total of 992,900 shares. Based on an average daily volume of 714,400 shares, the short-interest ratio is presently 2.3 days. Currently, 4.7% of the company’s shares are sold short.

Athira Pharma Price Performance

Shares of ATHA traded up $0.02 during midday trading on Friday, reaching $0.44. The stock had a trading volume of 301,744 shares, compared to its average volume of 453,745. The company has a market capitalization of $16.84 million, a P/E ratio of -0.14 and a beta of 2.90. The firm’s 50 day moving average price is $2.26 and its 200-day moving average price is $2.41. Athira Pharma has a 52 week low of $0.41 and a 52 week high of $4.30.

Athira Pharma (NASDAQ:ATHA) last announced its earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. On average, equities analysts forecast that Athira Pharma will post -2.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Rodman & Renshaw downgraded shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. BTIG Research downgraded Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th. JMP Securities lowered Athira Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 4th. Finally, Mizuho downgraded shares of Athira Pharma from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $5.00 to $0.50 in a research report on Thursday, September 19th.

Institutional Investors Weigh In On Athira Pharma

Large investors have recently bought and sold shares of the business. Rothschild Investment LLC bought a new position in shares of Athira Pharma in the 2nd quarter valued at approximately $34,000. Mirador Capital Partners LP acquired a new stake in shares of Athira Pharma in the first quarter worth $57,000. XTX Topco Ltd bought a new stake in shares of Athira Pharma during the 2nd quarter worth $60,000. Invst LLC bought a new position in Athira Pharma in the 2nd quarter worth $68,000. Finally, Forefront Analytics LLC lifted its position in Athira Pharma by 43.0% during the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock worth $72,000 after acquiring an additional 8,955 shares during the last quarter. 57.12% of the stock is currently owned by institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.